Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: Therapeutic potential in neurological diseases

Behavioural Pharmacology

Volumn 21, Issue 5-6, 2010, Pages 394-408

  Figueiredo, Cláudia P ^a,c   Pamplona, Fabrício A ^b,c   Mazzuco, Tĝnia L ^f   Aguiar, Aderbal S ^b   Walz, Roger ^c,d,e   Prediger, Rui Daniel Schröder ^c,d  

^a Programa de Pós Graduaçãoem Neurociências   (Brazil)

^b Centro de Ciencias Biologicas   (Brazil)

^c University Hospital   (Brazil)

^d FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^e HOSPITAL GOVERNADOR CELSO RAMOS   (Brazil)

^f STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Alzheimer's disease; animal models; central nervous system; GIP receptor; glucose dependent insulinotropic polypeptide; mesial temporal lobe epilepsy related to hippocampal sclerosis; neurological diseases; neuroplasticity; Parkinson's disease

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; INCRETIN;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; DENTATE GYRUS; EPILEPTIC STATE; EXERCISE; HIPPOCAMPUS; HUMAN; IMMUNOREACTIVITY; INSULIN RELEASE; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRAMIDAL NERVE CELL; REVIEW; SITTING; SUBVENTRICULAR ZONE; TEMPORAL LOBE EPILEPSY; TISSUE DISTRIBUTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; NERVOUS SYSTEM DISEASES; NEURONAL PLASTICITY; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 77955982823     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32833c8544     Document Type: Review

References (131)

1. Abe K, Kimura H (1996). Amyloid beta toxicity consists of a Ca(2+)-independent early phase and a Ca(2+)-dependent late phase. J Neurochem 67: 2074-2078.
2. Ahlskog JE, Muenter MD (2001). Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458.
3. Allain H, Bentue-Ferrer D, Akwa Y (2008). Disease-modifying drugs and Parkinson's disease. Prog Neurobiol 84:25-39.
4. Arendash GW, Lewis J, Leighty RE, McGowan E, Cracchiolo JR, Hutton M, et al. (2004). Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 1012:29-41.
5. Artero S, Tierney MC, Touchon J, Ritchie K (2003). Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand 107:390-393.
6. Baggio LL, Drucker DJ (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157.
7. Baldacchino V, Oble S, Decarie PO, Bourdeau I, Hamet P, Tremblay J, et al. (2005). The Sp transcription factors are involved in the cellular expression of the human glucose-dependent insulinotropic polypeptide receptor gene and overexpressed in adrenals of patients with Cushing's syndrome. J Mol Endocrinol 35:61-71.
8. Bell GI, Santerre RF, Mullenbach GT (1983). Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718.
9. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, et al. (2008). Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 86:326-338.
10. Blennow K, de Leon MJ, Zetterberg H (2006). Alzheimer's disease. Lancet 368:387-403.
11. Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R, et al. (2000). Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141:1228-1235.
12. Bonan CD, Walz R, Pereira GS, Worm PV, Battastini AM, Cavalheiro EA, et al. (2000). Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy. Epilepsy Res 39:229-238.
13. Boutin C, Hardt O, de Chevigny A, Core N, Goebbels S, Seidenfaden R, et al. (2010). NeuroD1 induces terminal neuronal differentiation in olfactory neurogenesis. Proc Natl Acad Sci\USA 107:1201-1206.
14. Boylan MO, Jepeal LI, Jarboe LA, Wolfe MM (1997). Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene in a mouse neuroendocrine tumor cell line. J Biol Chem 272:17438-17443.
15. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004). Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-134.
16. Brown JC, Dryburgh JR, Ross SA, Dupre J (1975). Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31:487-532.
17. Buchan AM, Polak JM, Capella C, Solcia E, Pearse AG (1978). Electronimmu-nocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry 56:37-44.
18. Buhren BA, Gasis M, Thorens B, Muller HW, Bosse F (2009). Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J Neurosci Res 87:1858-1870.
19. Cavalheiro EA, Leite JP, Bortolotto ZA, Turski WA, Ikonomidou C, Turski L (1991). Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia 32: 778-782.
20. Cayre M, Canoll P, Goldman JE (2009). Cell migration in the normal and pathological postnatal mammalian brain. Prog Neurobiol 88:41-63.
21. Chaudhuri KR, Healy DG, Schapira AH (2006). Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5:235-245.
22. Cotman CW, Su JH (1996). Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol 6:493-506.
23. Cotman CW, Berchtold NC (2002). Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 25:295-301.
24. Craft S, Watson GS (2004). Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3:169-178.
25. Creutzfeldt W (1979). The incretin concept today. Diabetologia 16:75-85.
26. Dal-Pizzol F, Klamt F, Vianna MM, Schroder N, Quevedo J, Benfato MS, et al. (2000). Lipid peroxidation in hippocampus early and late after status epilepticus induced by pilocarpine or kainic acid in Wistar rats. Neurosci Lett 291:179-182.
27. De Strooper B, Umans L, Van Leuven F, Van Den Berghe H (1993). Study of the synthesis and secretion of normal and artificial mutants of murine amyloid precursor protein (APP): cleavage of APP occurs in a late compartment of the default secretion pathway. J Cell Biol 121:295-304.
28. Ding KH, Zhong Q, Xie D, Chen HX, Della-Fera MA, Bollag RJ, et al. (2006). Effects of glucose-dependent insulinotropic peptide on behavior. Peptides 27:2750-2755.
29. Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A (1997). Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 17:5046-5061.
30. Doty RL (2008). The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 63:7-15.
31. Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, et al. (2003). Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144:4433-4445.
32. Engel J Jr (1996). Surgery for seizures. N Engl J Med 334:647-652.
33. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
34. Flatt PR (2008). Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes? Diabet Med 25:759-764.
35. Flood JF, Morley JE, Roberts E (1991). Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer disease. Proc Natl Acad Sci\USA 88:3363-3366.
36. Franco J, Prediger RD, Pandolfo P, Takahashi RN, Farina M, Dafre AL (2007). Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb. Life Sci 80:1906-1914.
37. Freir DB, Holscher C, Herron CE (2001). Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J Neurophysiol 85:708-713.
38. Fujita Y, Wideman RD, Asadi A, Yang GK, Baker R, Webber T, et al. (2010). Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 138:1966-1975.
39. Gage FH (2000). Mammalian neural stem cells. Science 287:1433-1438.
40. Gault VA, Holscher C (2008a). GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 587:112-117.
41. Gault VA, Holscher C (2008b). Protease-resistant glucose-dependent insulino-tropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. J Neurophysiol 99:1590-1595.
42. Gengler S, Gault VA, Harriott P, Holscher C (2007). Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. Exp Brain Res 179:621-630.
43. Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM, Mattson MP (2003). Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 87: 1137-1144.
44. Girard J (2008). The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 34:550-559.
45. Gispen WH, Biessels GJ (2000). Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23:542-549.
46. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998). The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346-1350.
47. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet N, Froguel P, et al. (1995). Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202-1208.
48. Haass C, De Strooper B (1999). The presenilins in Alzheimer's disease-proteolysis holds the key. Science 286:916-919.
49. Hannibal J (2002). Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. J Comp Neurol 453:389-417.
50. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008). Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 5:19.
51. Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y (2004). Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J Biol Chem 279:44795-44801.
52. Hauser WA, Rich SS, Lee JR, Annegers JF, Anderson VE (1998). Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 338: 429-434.
53. Hirsch E, Graybiel AM, Agid YA (1988). Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
54. Holscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol Aging (in press). doi:10.1016/j.neurobiolaging.2008.08.023.
55. Holscher C, Gengler S, Gault VA, Harriott P, Mallot HA (2007). Soluble beta-amyloid reversibly impairs hippocampal synaptic plasticity and spatial learning. Eur J Pharmacol 561:85-90.
56. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
57. Irwin DM (2009). Molecular evolution of mammalian incretin hormone genes. Regul Pept 155:121-130.
58. Jalonen TO, Charniga CJ, Wielt DB (1997). Beta-amyloid peptide-induced morphological changes coincide with increased K + and Cl-channel activity in rat cortical astrocytes. Brain Res 746:85-97.
59. Jepeal LI, Boylan MO, Michael Wolfe M (2008). GATA-4 upregulates glucose-dependent insulinotropic polypeptide expression in cells of pancreatic and intestinal lineage. Mol Cell Endocrinol 287:20-29.
60. Jhoo JH, Kim HC, Nabeshima T, Yamada K, Shin EJ, Jhoo WK, et al. (2004). Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res 155:185-196.
61. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK (1988). Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519-532.
62. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CH (2005). Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 280: 22297-22307.
63. Kirkitadze MD, Kowalska A (2005). Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. Acta Biochim Pol 52:417-423.
64. Kubota A, Yamada Y, Yasuda K, Someya Y, Ihara Y, Kagimoto S, et al. (1997). Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and-insensitive pathways. Biochem Biophys Res Commun 235:171-175.
65. LaBarre J, Still EV (1930). Studies on the physiology of secretin. Am J Physiol 91:649-653.
66. Lambon Ralph MA, Patterson K, Graham N, Dawson K, Hodges JR (2003). Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain 126:2350-2362.
67. Lampron A, Bourdeau I, Oble S, Godbout A, Schurch W, Arjane P, et al. (2009). Regulation of aldosterone secretion by several aberrant receptors including for glucose-dependent insulinotropic peptide in a patient with an aldoster-onoma. J Clin Endocrinol Metab 94:750-756.
68. Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, et al. (2004). Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 140:501-509.
69. Lee SC, Pervaiz S (2007). Apoptosis in the pathophysiology of diabetes mellitus. Int J Biochem Cell Biol 39:497-504.
70. Li L, Holscher C (2007). Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56:384-402.
71. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003). Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478.
72. Lois C, Alvarez-Buylla A (1994). Long-distance neuronal migration in the adult mammalian brain. Science 264:1145-1148.
73. Lu M, Wheeler MB, Leng XH, Boyd AE III (1993). The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). Endocrinology 132:94-100.
74. Luskin MB (1993). Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone. Neuron 11:173-189.
75. Lynn FC, Thompson SA, Pospisilik JA, Ehses JA, Hinke SA, Pamir N, et al. (2003). A novel pathway for regulation of glucose-dependent insulinotropic polypep-tide (GIP) receptor expression in beta cells. FASEB J 17:91-93.
76. Masuo Y, Matsumoto Y,Tokito F,Tsuda M, Fujino M (1993a). Effects of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) on the spontaneous release of acetylcholine from the rat hippocampus by brain microdialysis. Brain Res 611:207-215.
77. Masuo Y, Suzuki N, Matsumoto H, Tokito F, Matsumoto Y, Tsuda M, et al. (1993b). Regional distribution of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat central nervous system as determined by sandwich-enzyme immunoassay. Brain Res 602:57-63.
78. Mattson MP (2000). Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1:120-129.
79. Mazzuco TL, Chabre O, Sturm N, Feige JJ, Thomas M (2006). Ectopic expression of the gastric inhibitory polypeptide receptor gene is a sufficient genetic event to induce benign adrenocortical tumor in a xenotransplantation model. Endocrinology 147:782-790.
80. Mazzuco TL, Grunenwald S, Lampron A, Bourdeau I, Lacroix A (2010). Aberrant hormone receptors in primary aldosteronism. Horm Metab Res 42: 416-423.
81. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, et al. (2007). Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 27: 5394-5404.
82. Merkle FT, Mirzadeh Z, Alvarez-Buylla A (2007). Mosaic organization of neural stem cells in the adult brain. Science 317:381-384.
83. Messenger B, Clifford MN, Morgan LM (2003). Glucose-dependent insulino-tropic polypeptide and insulin-like immunoreactivity in saliva following sham-fed and swallowed meals. J Endocrinol 177:407-412.
84. Mora F, Exposito I, Sanz B, Blazquez E (1992). Selective release of glutamine and glutamic acid produced by perfusion of GLP-1 (7-36) amide in the basal ganglia of the conscious rat. Brain Res Bull 29:359-361.
85. Mortensen K, Christensen LL, Holst JJ, Orskov C (2003). GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114:189-196.
86. Murray CJ, Lopez AD, Jamison DT (1994). The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 72:495-509.
87. Nyberg J, Anderson MF, Meister B, Alborn AM, Strom AK, Brederlau A, et al. (2005). Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation. J Neurosci 25: 1816-1825.
88. Nyberg J, Jacobsson C, Anderson MF, Eriksson PS (2007). Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J Neurosci Res 85:2099-2119.
89. O'Brien JA, Ward A, Michels SL, Tzivelekis S, Brandt NJ (2009). Economic burden associated with Parkinson disease. Drug Benefit Trends 21: 179-190.
90. Oka JI, Goto N, Kameyama T (1999). Glucagon-like peptide-1 modulates neuronal activity in the rat's hippocampus. Neuroreport 10:1643-1646.
91. Okamoto N, Hori S, Akazawa C, Hayashi Y, Shigemoto R, Mizuno N, et al. (1994). Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J Biol Chem 269:1231-1236.
92. Parent JM (2003). Injury-induced neurogenesis in the adult mammalian brain. Neuroscientist 9:261-272.
93. Parkinson J (2002). An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 14:223-236. discussion 222.
94. Perry T, Greig NH (2005). Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2:377-385.
95. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002a). Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302:881-888.
96. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, et al. (2002b). A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300: 958-966.
97. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al. (2003). Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72:603-612.
98. Polak JM, Bloom SR, Sullivan SN, Facer P, Pearse AG (1977). Enkephalin-like immunoreactivity in the human gastrointestinal tract. Lancet 1:972-974.
99. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN (2006). The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 202:391-403.
100. Prediger RD, Franco JL, Pandolfo P, Medeiros R, Duarte FS, Di Giunta G, et al. (2007). Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: evidence for a dissociation between cognitive deficits and the glutathione system response. Behav Brain Res 177:205-213.
101. Prediger RD, Rial D, Medeiros R, Figueiredo CP, Doty RL, Takahashi RN (2009). Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) rat model of Parkinson's disease. Ann N Y Acad Sci 1170:629-636.
102. Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE, Figueiredo CP, Matheus FC, Ginestet L, et al. (2010). Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res 17:114-129.
103. Rojo AI, Montero C, Salazar M, Close RM, Fernandez-Ruiz J, Sanchez-Gonzalez MA, et al. (2006). Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci 24:1874-1884.
104. Ross SA, Brown JC, Dupre J (1977). Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26:525-529.
105. Samii A, Nutt JG, Ransom BR (2004). Parkinson's disease. Lancet 363:1783-1793.
106. Sanabria ER, Su H, Yaari Y (2001). Initiation of network bursts by Ca2 +-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy. J Physiol 532:205-216.
107. Sanabria ER, Silva AV, Spreafico R, Cavalheiro EA (2002). Damage, reorganization, and abnormal neocortical hyperexcitability in the pilocarpine model of temporal lobe epilepsy. Epilepsia 43 (Suppl 5):96-106.
108. Schapira AH (2004). Disease modification in Parkinson's disease. Lancet Neurol 3:362-368.
109. Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, et al. (2006). Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5:845-854.
110. Schmidt-Hieber C, Jonas P, Bischofberger J (2004). Enhanced synaptic plasticity in newly generated granule cells of the adult hippocampus. Nature 429: 184-187.
111. Sherwood NM, Krueckl SL, McRory JE (2000). The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon super-family. Endocr Rev 21:619-670.
112. Sims KB, Hoffman DL, Said SI, Zimmerman EA (1980). Vasoactive intestinal polypeptide (VIP) in mouse and rat brain: an immunocytochemical study. Brain Res 186:165-183.
113. Taguchi K, Yamagata HD, Zhong W, Kamino K, Akatsu H, Hata R, et al. (2005). Identification of hippocampus-related candidate genes for Alzheimer's disease. Ann Neurol 57:585-588.
114. Terranova JP, Kan JP, Storme JJ, Perreaut P, Le Fur G, Soubrie P (1996). Administration of amyloid beta-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound. Neurosci Lett 213:79-82.
115. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D (2001). Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 15:1559-1570.
116. Tseng CC, Jarboe LA, Landau SB, Williams EK, Wolfe MM (1993). Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat. Proc Natl Acad Sci\USA 90:1992-1996.
117. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI (1993). Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133:2861-2870.
118. Van Praag H, Kempermann G, Gage FH (1999). Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat Neurosci 2:266-270.
119. Volz A, Goke R, Lankat-Buttgereit B, Fehmann HC, Bode HP, Goke B (1995). Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma. FEBS Lett 373:23-29.
120. Walsh DM, Selkoe DJ (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-193.
121. Walter C, Murphy BL, Pun RY, Spieles-Engemann AL, Danzer SC (2007). Pilocarpine-induced seizures cause selective time-dependent changes to adult-generated hippocampal dentate granule cells. J Neurosci 27:7541-7552.
122. Walz R, Amaral OB, Rockenbach IC, Roesler R, Izquierdo I, Cavalheiro EA, et al. (1999). Increased sensitivity to seizures in mice lacking cellular prion protein. Epilepsia 40:1679-1682.
123. Walz R, Castro RM,Velasco TR, Carlotti CG Jr, Sakamoto AC, Brentani RR, et al. (2002). Cellular prion protein: implications in seizures and epilepsy. Cell Mol Neurobiol 22:249-257.
124. Wheeler DB, Randall A, Tsien RW (1994). Roles of N-type and Q-type Ca2 + channels in supporting hippocampal synaptic transmission. Science 264:107-111.
125. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, Pederson RA (1995). Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 136:4629-4639.
126. Wiebe S, Blume WT, Girvin JP, Eliasziw M (2001). A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 345:311-318.
127. Winder DG, Conn PJ (1993). Activation of metalotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine. J Neurosci 13:38-44.
128. Wirth KJ, Fink E, Rudolphi K, Heitsch H, Deutschlander N, Wiemer G (1999). Amyloid beta-(1-40) stimulates cyclic GMP production via release of kinins in primary cultured endothelial cells. Eur J Pharmacol 382:n27-n33.
129. Wyss-Coray T (2006). Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12:1005-1015.
130. Yalow RS, Berson SA (1960). Immunoassay of endogenous plasma insulin in man. J Clin Invest 39:1157-1175.
131. Yeung CM, Wong CK, Chung SK, Chung SS, Chow BK (1999). Glucose-dependent insulinotropic polypeptide gene expression in the stomach: revealed by a transgenic mouse study, in situ hybridization and immunohis-tochemical staining. Mol Cell Endocrinol 154:161-170.